Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN.
Guzauskas GF, et al. Among authors: rind dm.
J Manag Care Spec Pharm. 2021 Apr;27(4):455-468. doi: 10.18553/jmcp.2021.27.4.455.
J Manag Care Spec Pharm. 2021.
PMID: 33769850
Free PMC article.
Oral semaglutide added to current antihyperglycemic treatment was separately compared with (a) ongoing background antihyperglycemic treatment, (b) sitagliptin, (c) empagliflozin, and (d) liraglutide. Comparators sitagliptin, empagliflozin, and liraglutide were added to ong …
Oral semaglutide added to current antihyperglycemic treatment was separately compared with (a) ongoing background antihyperglycemic treatmen …